The Latest Clinical Research Result of MicroPort's DES
Recently, MicroPort published the latest result of its clinical studies including FIREMAN, FOCUS, and FIM of the third generation drug-eluting stent Firehawk, in the China Interventional Therapeutics 2010 (CIT).
FIREMAN is a clinical study of using domestic drug-eluting stents Firebird to treat complex coronary artery disease. It was started in 2006, and had already completed a 3-year follow-up by September 2010, which covered MACE, TLR/TVR, in-stent thrombosis and stroke, and especially the analysis of related factors causing in-stent thrombosis, as well as analysis of different subgroups of patients divided by the age, sex, diabetes or hyperlipidemia history. The follow-up result showed that cumulative cardiac death rate was 1.7%, the incidence of MI, TVR and MACE was 1.4%, 5% and 7.1% respectively, and the thrombosis rate was 1.36%.
FOCUS is currently the largest international preapproval multicenter clinical-registered study which was started in 2009, with a total of 5084 patients selected. The follow-up result obtained 6 month after the launch of Firebird2 Rapamycin-Eluting Coronary CoCr Stent in China, showed that cumulative cardiac death rate was 0.63%, the incidence of MI, TVR and MACE was respectively 1.07%, 0.3% and 1.8%, and the thrombosis rate was 0.61%.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.